Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Colistimethate Sodium

Colistimethate Sodium: A Last-Resort Antibiotic in the Era of Multidrug Resistance

Introduction

Colistimethate sodium (CMS), the prodrug of colistin (polymyxin E), is a potent antibiotic that has re-emerged in modern medicine as a critical therapeutic option against multidrug-resistant (MDR) Gram-negative bacterial infections. Initially introduced in the 1950s, colistin fell out of favor due to its nephrotoxicity and neurotoxicity. However, the escalating threat of antimicrobial resistance has necessitated its revival as a last-line treatment. 

Background and Chemical Properties

Colistimethate sodium is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus. It is a cyclic polypeptide with a fatty acid tail, exhibiting a detergent-like action that disrupts bacterial membranes.

  • Chemical Class: Polymyxins

  • Prodrug: Colistimethate sodium is inactive until hydrolyzed in vivo to colistin (polymyxin E).

  • Formulation: Available as intravenous (IV), intramuscular (IM), inhalational, and topical formulations.

Mechanism of Action

Colistin exerts its bactericidal effect by binding to the lipid A component of lipopolysaccharides (LPS) in the outer membrane of Gram-negative bacteria. This disrupts membrane integrity, increasing permeability and resulting in cell death. Unlike many antibiotics, colistin acts independently of bacterial replication, making it effective against dormant cells.

Pharmacokinetics and Pharmacodynamics

  • Absorption: Poor oral bioavailability; thus, used parenterally or by inhalation.

  • Distribution: Widely distributed in tissues; limited penetration into cerebrospinal fluid (CSF) unless meninges are inflamed.

  • Metabolism: CMS is hydrolyzed to colistin in the body.

  • Excretion: Mainly renal; dosage must be adjusted in renal impairment.

  • Half-life: CMS (~2-3 hours); colistin (~3-4 hours), but pharmacokinetics can vary.

Clinical Applications

CMS is reserved for treating infections caused by carbapenem-resistant organisms (CROs), particularly the "ESKAPE" pathogens:

  1. Pseudomonas aeruginosa

  2. Acinetobacter baumannii

  3. Klebsiella pneumoniae

  4. Enterobacter spp.

Indications

  • Ventilator-Associated Pneumonia (VAP): Especially effective via inhalation in combination with systemic therapy.

  • Bloodstream Infections (BSI): Used when caused by MDR Gram-negative bacteria.

  • Urinary Tract Infections (UTIs): Effective in complicated and catheter-associated infections.

  • Intra-abdominal Infections: Especially in cases of post-surgical infection or peritonitis.

  • Cystic Fibrosis: Inhaled colistin is a mainstay for chronic P. aeruginosa infections.

Dosage and Administration

CMS dosing is complex due to the conversion variability to colistin. Doses are often expressed in either international units (IU) or milligrams of colistin base activity (CBA):

Route Typical Dose
IV (Adults) Loading: 9 MIU, Maintenance: 4.5 MIU every 12 hours
Inhalation 1-2 MIU every 8-12 hours
Pediatric 75,000–150,000 IU/kg/day divided every 8-12 hours

Note: Dosage must be adjusted for renal dysfunction.

Adverse Effects

  1. Nephrotoxicity: Most common adverse effect; risk increases with higher doses and concomitant nephrotoxins (e.g., aminoglycosides, vancomycin).

  2. Neurotoxicity: Can manifest as dizziness, paresthesia, ataxia, seizures, or neuromuscular blockade.

  3. Bronchospasm: Especially with inhaled formulations.

  4. Allergic Reactions: Rare but possible, especially in topical use.

Drug Interactions

  • Nephrotoxic drugs: Co-administration with vancomycin, aminoglycosides increases renal toxicity.

  • Neuromuscular blockers: Potentiation of neuromuscular blockade can lead to respiratory depression.

Resistance Issues

The increased use of CMS has led to the emergence of colistin resistance, often due to modification of the bacterial LPS, reducing binding affinity.

  • mcr Genes: Mobile colistin resistance (mcr) genes encode enzymes that modify lipid A, conferring resistance. Detected in various Enterobacteriaceae.

  • Heteroresistance: Some bacterial populations exhibit variable sensitivity to colistin, complicating therapy.

Stewardship and Guidelines

Given its toxicity and resistance potential, CMS use should follow antimicrobial stewardship principles:

  • Use only when no safer alternatives are effective.

  • Always obtain microbiological confirmation and susceptibility testing.

  • Use combination therapy (e.g., with carbapenems, tigecycline) to minimize resistance development.

Current Guidelines

  • IDSA & ATS (2021): Recommends CMS for VAP and bloodstream infections caused by MDR organisms when alternatives are unavailable.

  • WHO: Lists colistin as a "Reserve" antibiotic under its AWaRe classification.

Research and Novel Applications

  1. Combination Therapy: Studies support combining CMS with carbapenems or rifampicin to enhance efficacy and reduce resistance emergence.

  2. Nanocarriers: Research is exploring liposomal and nanoparticle formulations to reduce toxicity and improve tissue targeting.

  3. Topical Use: Investigated for skin and soft tissue infections, and burn wound management.

  4. Biofilm Penetration: Colistin's membrane activity gives it potential to disrupt bacterial biofilms, especially in prosthetic infections.

Clinical Challenges

  • Dosing Confusion: Different units (IU vs. mg) create dosing errors.

  • Therapeutic Drug Monitoring (TDM): Limited availability of TDM complicates optimization.

  • Toxicity vs. Efficacy: Narrow therapeutic window demands careful balance.

Patient Counseling Points

  • Inform patients about the possibility of renal and neurological side effects.

  • Ensure adherence to inhaled therapy schedules in chronic infections.

  • Encourage adequate hydration to reduce nephrotoxicity risk.

  • Avoid concurrent nephrotoxic or neurotoxic drugs unless necessary.

Case Studies

  • Case 1: A 65-year-old with VAP due to carbapenem-resistant A. baumannii was successfully treated with IV colistimethate and meropenem, showing rapid clinical improvement.

  • Case 2: A 19-year-old with cystic fibrosis and chronic P. aeruginosa received inhaled CMS, leading to reduced hospital admissions and improved pulmonary function.

Conclusion

Colistimethate sodium has resurged as a vital weapon in the fight against multidrug-resistant Gram-negative infections. Its reintroduction underscores the critical need for judicious antibiotic use, robust antimicrobial stewardship, and ongoing research to balance efficacy with safety. As resistance trends evolve and therapeutic options narrow, CMS remains a cornerstone of last-resort antimicrobial therapy—effective when used wisely, cautiously, and in combination with comprehensive care strategies.

References

  • Nation RL, Li J, et al. Colistin in the 21st century. Antimicrobial Agents and Chemotherapy.

  • Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clinical Infectious Diseases.

  • IDSA Guidelines on the treatment of antimicrobial-resistant Gram-negative infections.

  • WHO AWaRe Classification of Antibiotics (2023).